Synthaverse S.A.
BML | WAR
Overview
Corporate Details
- ISIN(s):
- PLBMDLB00018 (+3 more)
- LEI:
- 259400OWZM67D079S374
- Country:
- Poland
- Address:
- LUBLIN UNIWERSYTECKA 10, 20-029 LUBLIN
- Website:
- https://synthaverse.com/en/
- Sector:
- Health Care
- Industry:
- Biotechnology
Description
We are a global pharmaceutical company whose goal is to provide the best, innovative and unique solutions for medicine. Our work is based on scientific and health knowledge. Along with our expert approach, it allows us to create reliable and unique products. We are constantly developing our competences. One of our leading achievements is on advancing field of immunotherapy. We manufacture one of the few drugs used internationally in the oncological immunotherapy of bladder cancer. We have also created an anti-tuberculosis vaccine, which is used to vaccinate all newborns in the country. It is widely used all over the world. Scientific knowledge and many years of experience in the cultivation of bacterial strains have allowed us to create one of the best probiotics on the market - Lakcid®, which is one of the few probiotic drugs available in the world.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2024-04-25 16:22 |
Regulatory News Service
Uzyskanie decyzji o pozwoleniu na użytkowanie Zakładu produkcyjnego Onko BCG - …
|
Polish | 1.7 KB | |
| 2024-04-22 09:42 |
Directors' Dealings
zal01_pdf_690436.pdf
|
Polish | 4.3 KB | |
| 2024-04-22 09:42 |
Directors' Dealings
Powiadomienie o transakcji na akcjach Emitenta - Content (PL)
|
Polish | 316 bytes | |
| 2024-04-10 08:32 |
Regulatory News Service
zal02_osw_RN_dot_KA_2023-12-31_pl.xhtml.xades
|
Polish | 10.6 KB | |
| 2024-04-10 08:32 |
Regulatory News Service
zal01_osw_RN_dot_KA_2023-12-31_pl.xhtml
|
Polish | 373.5 KB | |
| 2024-04-10 08:32 |
Regulatory News Service
zal15_osw_RN_dot_audytora_2023-12-31_pl.xhtml.xades
|
Polish | 10.6 KB | |
| 2024-04-10 08:32 |
Regulatory News Service
zal08_osw_RN_dot_audytora_2023-12-31_pl.xhtml
|
Polish | 1.0 MB | |
| 2024-04-10 08:32 |
Regulatory News Service
zal05_ocena_RN_dot_SF_2023-12-31_pl.xhtml.xades
|
Polish | 10.6 KB | |
| 2024-04-10 08:32 |
Regulatory News Service
zal03_ocena_RN_dot_SF_2023-12-31_pl.xhtml
|
Polish | 1.1 MB | |
| 2024-04-10 08:32 |
Regulatory News Service
zal07_osw_zarz_dot_rzetel_2023-12-31_pl_.xhtml.xades
|
Polish | 287.8 KB | |
| 2024-04-10 08:32 |
Regulatory News Service
zal12_osw_zarz_dot_rzetel_2023-12-31_pl_.xhtml
|
Polish | 339.8 KB | |
| 2024-04-10 08:32 |
Regulatory News Service
zal06_osw_zarz_dot_audyt_2023-12-31_pl.xhtml.xades
|
Polish | 276.8 KB | |
| 2024-04-10 08:32 |
Regulatory News Service
zal14_osw_zarz_dot_audyt_2023-12-31_pl.xhtml
|
Polish | 1005.7 KB | |
| 2024-04-10 08:32 |
Regulatory News Service
zal09_SzB_Synthaverse_2023_2024-04-09_pl.xhtml.xades
|
Polish | 6.0 KB | |
| 2024-04-10 08:32 |
Regulatory News Service
zal17_SzB_Synthaverse_2023_2024-04-09_pl.xhtml
|
Polish | 3.2 MB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
Lidds AB | Sweden | LIDDS | |
|
Lifecare ASA | Norway | LIFE | |
|
Lineage Cell Therapeutics Inc. | Israel | LCTX | |
|
Lipidor AB | Sweden | LIPI | |
|
Lipigon Pharmaceuticals AB | Sweden | LPGO | |
|
Lipum AB | Sweden | LIPUM | |
|
Lonza Group AG | Switzerland | LONN | |
|
LYSOGENE | France | LYS | |
|
Lytix Biopharma AS | Norway | LYTIX | |
|
MaaT Pharma | France | MAAT |